“…Demographic and clinical data were collected at enrollment, including age, sex, disease duration, smoking habits, previous medications, comorbidities, disease activity, physical function, and radiographic indicators, as we described previously. 15 , 16 Clinical data included disease duration, 28-joint tender and swollen joint count (28TJC and 28SJC), patient and provider global assessment of disease activity (PtGA and PrGA; range 0–10 cm), pain visual analogue scale (Pain VAS; range 0–10 cm), erythrocyte sedimentation rate [ESR; normal range 0–20 mm/h (female), 0–15 mm/h (male)], C-reactive protein (CRP; normal range 0–5 mg/L), rheumatoid factor (RF; normal range 0–20 mg/L, determined by nephelometry, Siemens Healthcare Diagnostics, Munich, Germany), and anti-cyclic citrullinated peptide antibody (ACPA, normal range 0–18 IU/mL, measured by enzyme-linked immunosorbent assay, Aesku Diagnostics, Wendelsheim, Germany). Disease activity was assessed with disease activity score in 28 joints with four variables including CRP (DAS28-CRP), simplified disease activity index (SDAI) and clinical disease activity index (CDAI).…”